(a) HeLa cells were pretreated for 30 min at 37 °C in serum-free DMEM with the inhibitors: 10 µM chlorpromazine (Chlor), 4 µM filipin (Filip) or 10 µM cytochalasin D (Cyto D). Subsequently, the following endocytosis markers were added: 25 μg/ml transferrin-Alexa 546 (Tfn; clathrin-mediated endocytosis), 1 μg/ml cholera toxin B subunit-Alexa 555 (CTB; caveolae-dependent endocytosis), or 100 μg/ml 70 kDa neutral dextran-tetramethylrhodamine (Dex; macropinocytosis). The cells were then maintained for 2 h at 37 °C before the fluorescence was measured by FACS. (b) HeLa cells were treated for 2.5 h with the inhibitors: 10 µM chlorpromazine (Chlor), 5 mM methyl-β-cyclodextrin (MβCD), 4 µM filipin (Filip), 10 µM nocodazole (Nocod), or 10 µM cytochalasin D (Cyto D). 20 μL MTS reagent was then added and the cells were incubated for 4 h at 37 °C. The absorbance of the soluble formazan product (λ = 490 nm) of MTS reduction was measured on a Synergy H1MF Multi-Mode microplate-reader, with a reference wavelength of 650 nm to subtract background. Cells treated with peptide-free carrier were used as control. The % viability was determined form the ratio of the absorbance of the treated cells to the control cells. ***, p < 0.0001; non-significant (ns), p > 0.05 compared with controls. 
